 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

First Trust Direct Indexing L.P. reduced its position in Grifols, S.A. (NASDAQ:GRFS  Free Report) by 13.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with...

Grifols, S.A. (NASDAQ:GRFS) Position Lowered by First Trust Direct Indexing L.P.

Grifols, S.A. (NASDAQ:GRFS  Get Free Report) has been assigned a consensus rating of Hold from the six analysts that are presently covering the firm, MarketBeat Ratings reports...

Grifols, S.A. (NASDAQ:GRFS) Given Consensus Rating of "Hold" by Analysts

This is a signal that GRFS's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Grifols SA (GRFS, $9.19) RSI Indicator left the oversold zone on September 11, 2023

This price move could be a signal that GRFS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

Grifols SA (GRFS, $9.59) price may climb as it broke lower Bollinger Band on Aug 29, 2023

Shares of Grifols, S.A. (NASDAQ:GRFS  Get Free Report) have been assigned a consensus rating of Moderate Buy from the six analysts that are covering the company, MarketBeat.com...

Analysts Set Grifols, S.A. (NASDAQ:GRFS) Target Price at $10.58

Grifols SA (GRFS, $9.73) price may climb as it broke lower Bollinger Band on Aug 24, 2023

StockNews.com downgraded shares of Grifols (NASDAQ:GRFS  Free Report) from a buy rating to a hold rating in a research report sent to investors on Tuesday. Separately, Morgan Stanley upgraded Grifols from an equal weight rating to an overweight rating in a research note on Wednesday, April ...

Grifols (NASDAQ:GRFS) Cut to "Hold" at StockNews.com

StockNews.com upgraded shares of Grifols (NASDAQ:GRFS  Free Report) from a hold rating to a buy rating in a research report report published on Monday morning. Separately, Morgan Stanley raised shares of Grifols from an equal weight rating to an overweight rating in a report on Wednesday, ...

Grifols (NASDAQ:GRFS) Lifted to "Buy" at StockNews.com

Shares of Grifols, S.A. (NASDAQ:GRFS Get Free Report) have been assigned an average recommendation of Moderate Buy from the six analysts that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. ...

Brokerages Set Grifols, S.A. (NASDAQ:GRFS) Target Price at $10.58

This is a signal that GRFS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Grifols SA (GRFS, $10.26) RSI Indicator left the overbought zone on August 01, 2023

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Watchers	735
52-Wk Low	$5.71
52-Wk High	$10.97

Market Cap	$2.41B
Volume (M)	295,827.00
52-Wk High	$10.97
52-Wk Low	$5.71

GRFS Grifols, SA

About

Feed

News

Sentiment

Earnings

Fundamentals